Y-mAbs Therapeutics to Present at 41st Annual J.P. Morgan Healthcare Conference
January 03 2023 - 9:00AM
Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq:
YMAB) a commercial-stage biopharmaceutical company focused on the
development and commercialization of novel, antibody-based
therapeutic products for the treatment of cancer, today announced
that its founder, President and Interim Chief Executive Officer,
Thomas Gad, will provide an overview and update on the Company's
business at the virtual 41st Annual J.P. Morgan Healthcare
Conference. The presentation will take place on Wednesday, January
11, 2023, at 5:15 PM Eastern Standard Time. The presentation can be
accessed via a live audio webcast.
About Y-mAbs Y-mAbs is a
commercial-stage biopharmaceutical company focused on the
development and commercialization of novel, antibody-based
therapeutic cancer products. In addition to conventional
antibodies, the Company’s technologies include bispecific
antibodies generated using the Y-BiClone platform and the SADA
platform. The Company’s broad and advanced product pipeline
includes one FDA-approved product, DANYELZA® (naxitamab-gqgk),
which targets tumors that express GD2, and one product candidate at
the registration-stage, OMBLASTYS® (omburtamab), which targets
tumors that express B7-H3.
Forward-Looking Statements
Statements in this press release about future
expectations, plans and prospects, as well as any other statements
regarding matters that are not historical facts, may constitute
“forward-looking statements” within the meaning of The Private
Securities Litigation Reform Act of 1995. Such statements include,
but are not limited to, statements about the potential of the
Company’s products and product candidates, including DANYELZA®, the
Y-BiClone technology and the SADA technology, including bi-specific
and SADA constructs, and the potential benefits thereof; the
Company’s business plans and prospects; collaborations or strategic
partnerships and the potential benefits thereof; the Company’s
business model and development, commercialization and product
distribution plans; current and future clinical and pre-clinical
studies and our research and development programs; potential for
DANYELZA territory and label expansion, and advancement of the
Y-BiClone technology and SADA technology; and other statements that
are not historical facts. Words such as ‘‘anticipate,’’
‘‘believe,’’ “contemplate,” ‘‘continue,’’ ‘‘could,’’ ‘‘estimate,’’
‘‘expect,’’ “hope,” ‘‘intend,’’ ‘‘may,’’ ‘‘might,’’ ‘‘plan,’’
‘‘potential,’’ ‘‘predict,’’ ‘‘project,’’ ‘‘should,’’ ‘‘target,’’
“will”, ‘‘would’’ “goal,” “aim,” and similar expressions are
intended to identify forward-looking statements, although not all
forward-looking statements contain these identifying words. Our
product candidates and related technologies are novel approaches to
cancer treatment that present significant challenges. Actual
results may differ materially from those indicated by such
forward-looking statements as a result of various factors,
including but not limited to: risks associated with our financial
condition and need for additional capital; risks associated with
our development work; cost and success of our product development
activities and clinical trials; the risks of delay in the timing of
our regulatory submissions or failure to receive approval of our
drug candidates; the risks related to commercializing any approved
pharmaceutical product, including the rate and degree of market
acceptance of our product candidates; development of our sales and
marketing capabilities and risks associated with failure to obtain
sufficient reimbursement for our products; the risks related to our
dependence on third parties, including for conduct of clinical
testing and product manufacture; our inability to enter into
partnerships; the risks related to government regulation; risks
related to market approval; risks associated with protection of our
intellectual property rights; risks related to employee matters and
managing growth; risks related to our common stock; risks
associated with the COVID-19 pandemic; risks associated with the
conflict between Russia and Ukraine and sanctions related thereto,
macroeconomic conditions, including inflation and uncertain global
credit and capital markets; and other risks and uncertainties
affecting the Company including those described in the “Risk
Factors” section included in our Annual Report on Form 10-K for the
year ended December 31, 2021 filed with the Securities and Exchange
Commission (the “SEC”) and in our other SEC filings, including our
Quarterly Reports on Form 10-Q for the quarters ending March 31,
2022, June 30, 2022, and September 30, 2022 as well as in our other
SEC filings. Any forward-looking statements contained in this press
release speak only as of the date hereof, and the Company
undertakes no obligation to update any forward-looking statement,
whether as a result of new information, future events or otherwise
except as required by law.
DANYELZA®, OMBLASTYS® and Y-mAbs® are registered trademarks of
Y-mAbs Therapeutics, Inc.
Contact:
Y-mAbs Therapeutics, Inc. 230 Park Avenue, Suite 3350New York,
NY 10169USA
+1 646 885 8505
E-mail: info@ymabs.com
Y mAbs Therapeutics (NASDAQ:YMAB)
Historical Stock Chart
From Jun 2024 to Jul 2024
Y mAbs Therapeutics (NASDAQ:YMAB)
Historical Stock Chart
From Jul 2023 to Jul 2024